Wegovy minimum age: the UK licence explained

The myth worth correcting first: 'some clinics will prescribe it to 16- or 17-year-olds'

This comes up regularly. The reasoning usually goes: 16-year-olds can consent to their own medical treatment in the UK, so surely they can access Wegovy if a prescriber agrees? Consent and licensing are separate matters. A patient's legal capacity to consent to treatment does not change what a medicine is licensed for. The Wegovy SmPC (the legally binding document that defines the authorised use) specifies adults. Prescribing it to someone under 18 would constitute off-label use, which carries a much higher bar of clinical justification and, for a weight-management medicine, would be very difficult to defend under current UK guidance.

The NHS medicines information for semaglutide is unambiguous on this point: Wegovy is for adults. A clinic that tells a 17-year-old they qualify is either misinformed or, in a worst-case scenario, not operating within the licence. If you've been quoted a prescription for a minor through an online service, that is a genuine red flag worth scrutinising carefully.

The position is the same for tirzepatide (Mounjaro), which is also licensed for adults only. Neither of the injectable GLP-1 medicines approved in the UK for weight management carry a paediatric indication at this time.

Why the age floor is set at 18, the clinical rationale

A question our prescribers hear most weeks is whether 17-year-olds close to their 18th birthday might be an exception, and our Wegovy age guidance explains in detail why they are not. The reason is rooted in how clinical trials work: the STEP 1 trial that underpinned Wegovy's approval enrolled adults, and the safety and efficacy data the MHRA used to grant the UK marketing authorisation was generated in adult populations. Without comparable paediatric trial data reviewed and approved by the regulator, extending the licence to under-18s is not possible, regardless of how mature a young person is or how significant their weight-related health needs are.

There is also a physiological consideration. Adolescents are still developing, and the long-term effects of GLP-1 receptor agonists on bone density, growth, and hormonal development in younger patients have not been sufficiently studied to support a UK licence. NICE's appraisal of semaglutide (Wegovy) under TA875 likewise scopes its recommendations to adults, reinforcing that the NHS pathway is not applicable to those under 18 either.

This does not mean weight management support is unavailable to young people, it means the route is different. Paediatric obesity is managed through specialist children's services, where clinical decisions are made with a different evidence base and different safeguards.

What about the Wegovy tablet, does it have a different age threshold?

No. When the MHRA approved oral semaglutide (the Wegovy 25 mg tablet) on 11 June 2026 as the first oral GLP-1 medicine licensed for weight management in the UK, the indication was for adults only. If you want to understand what age you can take Wegovy, whether as the tablet or the injection, the answer is the same: the minimum age applies to both, and the tablet's approval does not open a new route for younger patients. For anyone curious about how the tablet compares to the injection in general, the Wegovy overview covers the key differences in dosing format and the trial evidence behind each.

Storage and administration differ significantly from the injection (no refrigeration is needed, and it is taken first thing in the morning before eating) but the patient group it is licensed for is identical: adults aged 18 and over, with a BMI of 30 or above, or 27 or above alongside a weight-related health condition.

If you are approaching 18, or asking on behalf of someone who is

Turning 18 does not automatically make someone suitable for Wegovy. Eligibility is assessed against the full clinical picture: BMI, any weight-related conditions, current medicines, medical history and lifestyle context. The prescriber looks at the whole person, not just the birthday. That said, once someone turns 18 they can proceed through a legitimate clinical pathway like the one offered by our pharmacy team.

For families supporting a younger person with weight-related health concerns right now, the appropriate route is a GP referral to a specialist paediatric weight management service. That pathway sits outside GLP-1 medicines entirely and involves dietitians, paediatricians and, where relevant, specialist clinical teams. Costs and waiting times vary; a GP is the starting point. A quick look at how Wegovy is priced privately may be useful context for when an adult in the family does become eligible.

When someone in your household does reach the right age and wants to explore whether they are clinically suitable, our page on semaglutide age requirements is a helpful first read before speaking to our prescribers, who review every consultation the same day. Every consultation at nume is reviewed the same day by a GPhC-registered Independent Prescriber, at no charge.